MA33938B1 - 5-alcynyl-pyrimidines - Google Patents

5-alcynyl-pyrimidines

Info

Publication number
MA33938B1
MA33938B1 MA35082A MA35082A MA33938B1 MA 33938 B1 MA33938 B1 MA 33938B1 MA 35082 A MA35082 A MA 35082A MA 35082 A MA35082 A MA 35082A MA 33938 B1 MA33938 B1 MA 33938B1
Authority
MA
Morocco
Prior art keywords
pyrimidine
alkynyl
medicament
excessive
preparing
Prior art date
Application number
MA35082A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Siegfried Schneider
Dirk Kessler
Der Veen Lars Van
Tobias Wunberg
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42140100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33938(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33938B1 publication Critical patent/MA33938B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA35082A 2010-01-26 2012-07-18 5-alcynyl-pyrimidines MA33938B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10151722 2010-01-26
PCT/EP2011/051060 WO2011092197A1 (en) 2010-01-26 2011-01-26 5-alkynyl pyrimidines and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
MA33938B1 true MA33938B1 (fr) 2013-01-02

Family

ID=42140100

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35082A MA33938B1 (fr) 2010-01-26 2012-07-18 5-alcynyl-pyrimidines

Country Status (24)

Country Link
US (1) US8618111B2 (enEXAMPLES)
EP (1) EP2528910B1 (enEXAMPLES)
JP (1) JP5670479B2 (enEXAMPLES)
KR (1) KR20130030742A (enEXAMPLES)
CN (1) CN102781931A (enEXAMPLES)
AP (1) AP2012006361A0 (enEXAMPLES)
AR (1) AR080019A1 (enEXAMPLES)
AU (1) AU2011209343A1 (enEXAMPLES)
BR (1) BR112012018454A2 (enEXAMPLES)
CA (1) CA2787396A1 (enEXAMPLES)
CL (1) CL2012001926A1 (enEXAMPLES)
CO (1) CO6592046A2 (enEXAMPLES)
EA (1) EA201201049A1 (enEXAMPLES)
EC (1) ECSP12012110A (enEXAMPLES)
IN (1) IN2012DN06600A (enEXAMPLES)
MA (1) MA33938B1 (enEXAMPLES)
MX (1) MX2012008359A (enEXAMPLES)
PE (1) PE20121527A1 (enEXAMPLES)
PH (1) PH12012501521A1 (enEXAMPLES)
SG (1) SG182676A1 (enEXAMPLES)
TN (1) TN2012000370A1 (enEXAMPLES)
TW (1) TW201139412A (enEXAMPLES)
UY (1) UY33198A (enEXAMPLES)
WO (1) WO2011092197A1 (enEXAMPLES)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
US8466162B2 (en) * 2011-01-26 2013-06-18 Boehringer Ingelheim International Gmbh 5-alkynyl-pyridines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
EP0674627A1 (en) 1992-12-18 1995-10-04 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5622954A (en) 1994-05-11 1997-04-22 Fmc Corporation 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides
DE60142236D1 (de) * 2000-07-24 2010-07-08 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
WO2004083235A2 (en) * 2003-03-19 2004-09-30 Exelixis Inc. Tie-2 modulators and methods of use
US20060205740A1 (en) * 2003-08-14 2006-09-14 Reno Michael J Chemical compounds
US20080027076A1 (en) 2003-12-24 2008-01-31 Astrazeneca Ab Pyrimidines With Tie2 (Tek) Activity
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006082373A1 (en) 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
EP1846399A1 (en) 2005-02-01 2007-10-24 AstraZeneca AB Pyrimidine compounds having tie2 (tek) inhibitory activity
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
US20070135437A1 (en) 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
WO2006106721A1 (ja) * 2005-03-30 2006-10-12 Shionogi & Co., Ltd. チロシンキナーゼ阻害作用を有するピリミジン誘導体
JP2008534565A (ja) 2005-03-31 2008-08-28 アストラゼネカ アクチボラグ Tie2阻害活性のあるアミノピリミジン誘導体
BRPI0706395A2 (pt) * 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
US20090325957A1 (en) 2006-08-24 2009-12-31 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US8318736B2 (en) 2006-12-29 2012-11-27 Janssen R&D Ireland HIV inhibiting 5,6-substituted pyrimidines
EP2022785A1 (en) 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
PL2323992T3 (pl) * 2008-07-29 2017-01-31 Boehringer Ingelheim International Gmbh 5-alkinylo-pirymidyny
JP2010018601A (ja) * 2009-02-16 2010-01-28 Tetsuya Nishio 複素環化合物、その製造法および用途
US8633183B2 (en) * 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines

Also Published As

Publication number Publication date
JP5670479B2 (ja) 2015-02-18
EA201201049A1 (ru) 2013-02-28
SG182676A1 (en) 2012-08-30
JP2013518078A (ja) 2013-05-20
CA2787396A1 (en) 2011-08-04
IN2012DN06600A (enEXAMPLES) 2015-10-23
PE20121527A1 (es) 2012-11-21
CL2012001926A1 (es) 2012-11-30
WO2011092197A1 (en) 2011-08-04
AP2012006361A0 (en) 2012-08-31
MX2012008359A (es) 2012-08-08
ECSP12012110A (es) 2012-09-28
UY33198A (es) 2011-08-31
US8618111B2 (en) 2013-12-31
TW201139412A (en) 2011-11-16
BR112012018454A2 (pt) 2016-04-19
AR080019A1 (es) 2012-03-07
US20120028958A1 (en) 2012-02-02
AU2011209343A1 (en) 2012-08-02
KR20130030742A (ko) 2013-03-27
CN102781931A (zh) 2012-11-14
CO6592046A2 (es) 2013-01-02
EP2528910A1 (en) 2012-12-05
PH12012501521A1 (en) 2012-10-22
EP2528910B1 (en) 2015-03-18
TN2012000370A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
TN2009000551A1 (fr) Nouveaux composes chimiques
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA33492B1 (fr) Inhibiteurs de bace
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA33939B1 (fr) 5-alcynyl-pyrimidines
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA38146A1 (fr) Nouveaux dérivés du benzimidazole comme antagonistes ep4
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MA32506B1 (fr) Nouveaux composes
PH12013500152A1 (en) New aminopyrazoloquinazolines
MA39193A1 (fr) Modulateurs du gpr6 à base de tétrahydropyridopyrazines
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA34831B1 (fr) Amides d'aminoindanes presentant une forte activite fongicide et leurs compositions phytosanitaires
MA33509B1 (fr) Dérivés de l'oxazine et leur utilisation dans le traitement de troubles neurologiques
MA20150065A1 (fr) Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA35895B1 (fr) Inhibiteurs d'iap
MA32158B1 (fr) Thiazolyldihydroindazoles
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
MA33222B1 (fr) 5-alcynylpyridines
MA33938B1 (fr) 5-alcynyl-pyrimidines
MA37444A1 (fr) Utilisation intra-utérine de 18-méthyl-15 bêta, 16-bêta-méthylène-19-nor-20-spirox-4-en-3-ones, système intra-utérin contenant du 18-méthyl-15 bêta, 16-bêta-méthylène-19-nor-20-spirox-4-en-3-ones, et utilisation desdits composés pour la contraception et les traitements gynécologiques